Strides Arcolab receives NDA approvals from USFDA

New Delhi, June 6 (UNI) Pharma company Strides Arcolab Ltd today said it has received approvals from the USFDA to manufacture and market two new drug applications (NDA) Lamivudine Stavudine and Lamivudine Zidovudine.

The drugs will be available in strenghts of 150 mg-40 mg and 50-300 mg respectively, a statement said.

Both the drugs are under the expedited review provisions of the President's Emergency Plan for Aids Relief (PEPFAR) programme.

Vice Chairman and Managing Director of the company Arun Kumar said, ''We now have approvals for all key front line HIV/AIDS medicines. This, combined with our pipeline of second line drugs, will make us a significant player in the quality, affordable multi-source ARVs business segment.'' The company partners with the Clinton Foundation to ensure availability of affordable quality generic ARVs in least-developed countries.

UNI